Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Break Below 200-Day Moving Average - Should You Sell?

Key Points

• Recursion shares fell below their 200-day moving average, trading as low as $3.27 and last at $3.33, with trading volume of about 20.4 million shares.
• Analyst views are mixed, but the consensus rating is Hold, with an average price target of $8.18; individual targets cited ranged from $5.90 to $8.00.
• The company reported a quarterly loss of $0.22 per share, in line with expectations, while revenue of $18.55 million exceeded the $14.81 million consensus estimate.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $3.49 and traded as low as $3.27. Recursion Pharmaceuticals shares last traded at $3.33, with a volume of 20,429,060 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Morgan Stanley set a $5.90 price target on Recursion Pharmaceuticals in a research note on Friday, October 16th. Wall Street Zen raised Recursion Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. Finally, Needham & Company LLC restated a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $8.18.

Recursion Pharmaceuticals Stock Down 7.2%

The stock's fifty day simple moving average is $3.78 and its two-hundred day simple moving average is $3.49. The firm has a market cap of $2.07 billion, a PE ratio of -3.70 and a beta of 1.15.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, November 2nd. The company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. The business had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. During the same period in the previous year, the company posted ($0.36) earnings per share. On average, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In related news, CEO Najat Khan sold 22,408 shares of the firm's stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the sale, the chief executive officer owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the firm's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the transaction, the director owned 6,108,287 shares in the company, valued at approximately $29,564,109.08. This trade represents a 0.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 167,408 shares of company stock worth $701,276 over the last quarter. 6.65% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new position in Recursion Pharmaceuticals in the 1st quarter worth $7,370,000. Bank of America Corp DE grew its holdings in Recursion Pharmaceuticals by 18.2% during the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company's stock valued at $7,665,000 after buying an additional 384,486 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Recursion Pharmaceuticals by 29.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company's stock valued at $4,490,000 after acquiring an additional 331,048 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Recursion Pharmaceuticals by 15.2% in the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company's stock worth $8,015,000 after purchasing an additional 344,035 shares during the last quarter. Finally, California State Teachers Retirement System raised its holdings in shares of Recursion Pharmaceuticals by 64.0% during the 1st quarter. California State Teachers Retirement System now owns 574,637 shares of the company's stock worth $1,764,000 after acquiring an additional 224,332 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.